Small Cell Lung Cancer (SCLC) Treatment Market Report | Size, Share & Future Outlook 2030
SCLC 患病率的上升以及小细胞肺癌治疗市场的疗法和联合疗法的可用性是推动 SCLC 治疗市场增长的值得注意因素。产品发布和快速产品批准也是在 2020 年至 2030 年期间提供利润丰厚的市场机会的关键因素。
小细胞肺癌 (SCLC) 是一种侵袭性肺癌，其特征是肺癌中某些细胞的快速且不受控制的生长。肺。 SCLC 的主要危险因素是吸烟，症状因人而异。 SCLC 分为主要阶段，例如局限性疾病和广泛性疾病。受 SCLC 影响的个体更常接受化疗和放射治疗，对于早期癌症，可能会建议进行手术。
增长驱动因素：
SCLC 患病率和治疗药物可用性的上升
根据 Genentech, Inc. 2023 年报告，SCLC 约占所有难以治疗的肺癌病例的 13%。因此，SCLC是最具侵袭性的肺癌类型，具有5年生存率。目前 SCLC 的治疗选择有限，并且对提高生存率的新型有效治疗方法的需求尚未得到满足。例如，一线铂类化疗（CT）是推荐的主要治疗方法。此外，联合化疗药物如“顺铂”和“卡铂”是最推荐与“依托泊苷”联合使用治疗小细胞肺癌的药物。
美国国家癌症研究所报告显示，小细胞肺癌占支气管癌的近15% 。然而，由于患者对放化疗反应良好，美国 SCLC 的总体发病率在过去几十年中有所下降。例如，胸部放射还改善了患者的长期医疗保健结果。因此，人口中 SCLC 患病率的上升以及特定治疗方法的可用性是 2020-2030 年预测期内全球 SCLC 市场增长的关键因素。
联合治疗小细胞肺癌 (SCLC) 治疗市场
肺癌治疗的联合疗法是肺癌研究的最新进展，临床研究显示成功治疗的患者可提高 SCLC 患者的总生存率。化疗药物与免疫疗法相结合就是针对 SCLC 的联合疗法的例子之一。 Atezolizumab (Tecentriq) 是 FDA 批准的一种 SCLC 治疗药物，与“卡铂和依托泊苷”联合使用，作为患有广泛期 SCLC 成人的一线治疗。同样，临床研究人员已经发现两种药物的组合可以降低 SCLC 患者的死亡率，SCLC 是肺癌中最具侵袭性的一种形式。由于大多数患者通过化疗免疫疗法对 SCLC 作为一线治疗反应积极，因此癌症复发的可能性很高。因此，联合疗法，例如化疗药物“Topotecan (Hycamtin)”和研究药物“Berzosertib”，负责抑制有助于修复 SCLC 引起的受损 DNA 的蛋白质。因此，预计上述因素将有利于 2020-2030 年的市场增长。
市场机会
产品上市和快速产品批准
大多数 SCLC 患者对化疗和免疫疗法的初始治疗有反应。然而，尽管进行了额外的治疗，癌症通常仍会进展，大多数患者会在数周或数月内死亡。因此，快速的产品批准很可能为市场从 2020 年到 2030 年呈指数级增长提供有利可图的机会。例如，2020 年 3 月，美国食品和药物管理局 (FDA) 宣布批准“Durvalumab”与“依托泊苷”和“卡铂”或“顺铂”作为广泛期 SCLC 患者的一线治疗。此外，2019年3月，美国FDA批准“Tecentriq”用于治疗SCLC。新获批的“Tecentriq”是第二个获批用于晚期SCLC患者的免疫治疗药物，也是一线治疗药物。
未来趋势
CAR T细胞疗法提供新的治疗选择
治疗的新研究方法SCLC 在未来几年可能会展现出巨大的前景。 CAR-T 细胞疗法就是在临床前研究中为 SCLC 展现出巨大前景的一个例子。 CAR T细胞疗法是一种“活体药物”，负责显示药理活性，例如重新设计患者的T细胞，使其能够附着在癌细胞上并摧毁它们。 Delta样配体3（DLL3）是一种在SCLC肿瘤细胞表面发现的抗原，包括肺癌、前列腺癌、乳腺癌、胰腺癌和肠道的高级别癌症，因此，针对DDL3的CAR T细胞疗法可以提供新的治疗方案。这些疾病的治疗方案。因此，CAR T 细胞疗法的进步将在不久的将来成为新的市场趋势，最终推动 2020 年至 2030 年的市场增长。
报告细分和范围：
全球 SCLC 治疗市场分为治疗、阶段和最终用户。根据治疗方法，市场分为化疗、放射治疗、免疫治疗等。从阶段来看，SCLC治疗市场分为粗放阶段和有限阶段。 SCLC 治疗市场，按最终用户划分，SCLC 治疗市场分为医院、专科诊所、家庭护理机构等。 SCLC 治疗市场根据地理位置分为北美（美国、加拿大和墨西哥）、欧洲（德国、法国、意大利、英国、西班牙和欧洲其他地区）、亚太地区（澳大利亚、中国） 、日本、印度、韩国和亚太其他地区）、中东和非洲（南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷、以及南美洲和中美洲其他地区）。
细分分析：
根据治疗，SCLC 治疗市场分为化疗、放射治疗、免疫治疗等。 2022年，化疗领域占据最大市场份额。小细胞肺癌最初往往对化疗反应良好。 SCLC 的化疗药物通常通过静脉 (IV) 输注方式给药。 SCLC 最常见的两种化疗药物包括“依托泊苷加顺铂”和“依托泊苷加卡铂”。此外，“Topotecan 和 Lurbinectedin”是可供 SCLC 患者服用的化疗药物。因此，化疗药物与 SCLC 治疗相结合的可用性预计将在 2020-2030 年影响该细分市场的市场。
基于分期的 SCLC 治疗市场分为广泛期和有限期。 2022年，大型舞台细分市场占据最大份额。预计该细分市场在 2022 年至 2030 年期间将实现最高的复合年增长率。广泛期 SCLC 广泛扩散至肺部、淋巴结、胸部和其他身体部位（包括骨髓）。根据美国癌症协会 2023 年的报告，约三分之二的 SCLC 患者患有广泛的疾病，其中癌症首先被发现。因此，随着疾病广泛期的上升，化疗是更好地控制癌症的一线治疗选择。
根据最终用户，SCLC 治疗市场分为医院、专科诊所、家庭护理机构等。 2022年，医院领域占据最大的市场份额。然而，预计 2022 年至 2030 年期间，专科诊所的复合年增长率将达到最快。 SCLC 治疗主要在医院提供，由肺科医生、肿瘤内科医生、放射肿瘤科医生和胸外科医生组成的团队密切合作，为 SCLC 制定定制的治疗计划。治疗计划包括化疗、放射治疗和手术。此外，医院还为 SCLC 和各种医疗状况提供多学科治疗。此外，还提供各种支持服务，以改善患者的生活质量和全面且富有同情心的护理。这些综合服务包括肺康复、戒烟、心理和社会支持以及综合治疗。纽约大学朗格医院 (NYU Langone Hospital) 就是 SCLC 治疗的例子之一。因此，医院提供的定制治疗计划和支持服务预计将是影响 2020 年至 2030 年市场增长的主要因素。
小细胞肺癌 (SCLC) 治疗市场，按治疗方式 – 2022 年和 2030 年
区域分析：
根据地理位置，SCLC治疗市场分为五个关键区域：北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。对北美市场的分析主要集中在三个主要国家——美国、加拿大和墨西哥。 2022年，美国将占据小细胞肺癌治疗市场的最大份额。根据耶鲁大学医学2023年报告，小细胞肺癌每年占美国所有肺癌诊断的15%。因此，仅在美国，SCLC 病例不断增加，美国对 SCLC 药物以降低死亡率的需求就很高。同样，治疗 SCLC 药物的快速产品批准预计将进一步促进 2022 年至 2030 年的市场增长。例如，2020 年 6 月，Jazz Pharmaceuticals plc 宣布美国 FDA 批准 Zepzelcaa” 用于治疗在铂类化疗期间或之后疾病进展的转移性 SCLC 成年患者。“Zepzelcaa”现已在美国上市，将推动市场增长2020 年至 2030 年。
同样，2022 年至 2030 年期间，亚太地区的 SCLC 治疗市场复合年增长率最高。在亚太地区，中国在 2020 年至 2030 年期间占据 SCLC 治疗市场的主要份额。中国小细胞肺癌的治疗是2022-2030年市场增长的主导因素。根据记录，2021年7月，阿斯利康宣布在中国批准“Imfinzi（durvalumab）”作为所有患有该病的成年患者的一线治疗中国国家药品监督管理局的批准基于 CASPIAN III 期试验的积极结果，临床试验显示“Imfinzi plus”化疗对小细胞肺癌患者的生存率具有统计学意义和临床意义的改善患者与单纯化疗相比。作为广泛开发计划的一部分，“Imfinzi Plus”还在亚得里亚海 III 期试验中对患有局限性 SCLC 的患者进行同步放化疗后进行测试。因此，预计上述因素将在 2020-2030 年影响亚太地区 SCLC 治疗市场。
竞争格局和主要公司：
F. Hoffmann-La Roche、Bristol Myers Squibb、AstraZeneca、Jazz Pharmaceuticals plc、Merck KgaA、Dr. Reddy's Laboratories, Inc.、GlaxoSmithKline (GSK)、Pfizer、Regeneron 和 Janssen 是全球一些著名的 SCLC 治疗制造商SCLC 治疗市场。这些公司专注于新技术、现有产品的进步和地域扩张，以满足全球日益增长的消费者需求，并扩大其专业产品组合的产品范围。 2022年11月，再生元制药公司宣布美国FDA批准其“PD-1抑制剂“Libtayo（cemiplimab-rwlc）”与铂类化疗联合用于成人患者的一线治疗。Libtayo还被批准用于延长晚期 SCLC 患者的生存期。
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The extensive stage segment dominated the global small cell lung cancer (SCLC) treatment market and accounted for the largest revenue in 2022.
F. Hoffmann-La Roche, Bristol Myers Squibb, AstraZeneca, Jazz Pharmaceuticals plc, Merck KgaA, Dr. Reddy's Laboratories, Inc., GlaxoSmithKline (GSK), Pfizer, Regeneron, and Janssen, and among others are among the leading companies operating in the small cell lung cancer (SCLC) treatment market.
Based on treatment, the chemotherapy segment took the forefront lead in the small cell lung cancer (SCLC) treatment market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
Rising prevalence of SCLC and the availability of therapeutics and combination therapy for the small cell lung cancer treatment market are the factor responsible for the overall market growth.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by a rapid and uncontrolled growth of certain cells in the lungs. The primary risk factor of SCLC is the consumption of tobacco and smoking, with symptoms varying from person to person. The SCLC is broken down into main stages, such as limited-stage disease and extensive-stage disease. The SCLC-affected individuals are more often treated with chemotherapy and radiation therapy, and in the case of early-stage cancer, surgery may be recommended.
The List of Companies - Small Cell Lung Cancer (SCLC) Treatment Market
- F. Hoffmann-La Roche
- Bristol Myers Squibb
- AstraZeneca
- Jazz Pharmaceuticals plc
- Merck KgaA
- Dr. Reddy's Laboratories, Inc.
- GlaxoSmithKline (GSK)
- Pfizer
- Regeneron
- Janssen
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For